The Determination and Clinical Significance of Prostaglandin E2 in Blood and Urine of Patients with Renal Colic

Background: This study explores the role of prostaglandin E-2(PGE(2)) in the etiology of urolithiasis in acute renal colic by analyzing the PGE(2) levels in blood and urine throughout the clinical course of renal colic. Methods: From June 2015 to November 2017, a total of 60 patients with acute renal colic were enrolled in the study. Blood and urine samples were taken before and after administration of drug to inhibit prostaglandin synthesis; further blood and urine samples were obtained from the patients 2 weeks after their recovery. The concentration of PGE(2) in blood and urine samples was determined by using a Human Prostaglandin E-2 ELISA Kit. Results: The mean concentration of PGE(2) was 420 +/- 50.3 ng/L in blood and 600 +/- 70.1 ng/L in urine when the patients had renal colic. After drug therapy, these concentrations fell to 300 +/- 40.4 ng/L in blood and 500 +/- 54.5 ng/L in urine. After 2 weeks the PGE(2) concentration was 220 +/- 47.5 ng/L and 300 +/- 50.2 ng/L in blood and urine, respectively. Compared with PGE(2) levels after medication, these concentrations were significantly higher during acute renal colic (p < 0.05). Conclusions: The synthesis and release of PGE(2) increase at the onset of renal colic, suggesting that PGE(2) plays an important role in acute renal colic. Administration of a prostaglandin synthesis inhibitor is a reliable way to treat renal colic.